Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane

Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in child...

Full description

Journal Title: Journal of Clinical Oncology Vol. 26; no. 7; pp. 1106 - 1111
Authors: Eric Larsen, Elly Barry, Lynda Vrooman, Suzanne Dahlberg, Donna Neuberg, Barbara Asselin, Uma Athale, Luis Clavell, Albert Moghrabi, Yvan Samson, Marshall Schorin, Harvey Cohen, Steven Lipshultz, Stephen Sallan, Lewis Silverman
Format: Article
Language: English
Published: March 1, 2008
Online Access: Full Text
Summary: Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
ISSN: 0732-183X
DOI: 10.1200/JCO.2007.12.2481